226330 SYNTEKABIO INC

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology NEO-ARS™ at the CRI-ENCI-AACR International Cancer Immunotherapy Conference (): Translating Science into Survival, Sep. 28 – Oct. 1, 2022.

Hyun Joo, Ph.D., senior principal scientist at the Syntekabio USA, will present AI-driven 3D structure-based neoantigen prediction and its implication on immuno-oncology therapy during Poster Session B. The full abstract is included in the conference app and will be available online via the AACR journal, Cancer Immunology Research.

WHAT:      AI-driven 3D structure-based neoantigen prediction and its implication on immuno-oncology therapy 

DATE:      Friday, Sep. 30 

TIME:      12:15 pm – 2:15 pm 

LOCATION:             New York Hilton Midtown, Americas Hall I  

NOTES:         Syntekabio USA President Kilyoung Kim is available to speak with the media onsite. For one-on-one meeting request and information about Syntekabio’s AI drug discovery cloud platform services, contact the New York office at +1 (212) 371-2544 or .  

###

About Syntekabio

Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its US operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at . 





For original news story, please visit 

Attachment



Full Name : Sabina Lee
Company : Syntekabio USA | WMSG
Phone Number : 2014021400
Website : 
Email :  
EN
26/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNTEKABIO INC

 PRESS RELEASE

POLARIS(qb) and Syntekabio sign MOU for Collaborative AI and Quantum-p...

Syntekabio Inc. POLARIS(qb) and Syntekabio sign MOU for Collaborative AI and Quantum-powered Drug Development Service 31-Aug-2023 / 16:30 CET/CEST The issuer is solely responsible for the content of this announcement. POLARISqb and Syntekabio sign MOU for Collaborative AI and Quantum-powered Drug Development Service   NEWS RELEASE BY SYNTEKABIO, INC. Durham, NC | August 31, 2023 09:00 AM Eastern Daylight Time POLARISqb, the first company in the world to develop a drug discovery engine that utilizes the optimization power of quantum computing, announced that it has signed an M...

 PRESS RELEASE

Syntekabio Inc.: Syntekabio and metaclipse sign for joint research on ...

Syntekabio Inc. Syntekabio Inc.: Syntekabio and metaclipse sign for joint research on personalized immunotherapy for cancer 01-Aug-2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Syntekabio and Metaclipse sign MOU for Joint Research on Personalized Immunotherapy for Cancer   NEWS RELEASE BY SYNTEKABIO, INC. DAEJEON, Rep. of Korea | July 31, 2023 02:58 PM Eastern Daylight Time Syntekabio (KOSDAQ: 226330), an Artificial Intelligence (AI) based drug development company, announced that it has signed a MOU with Metaclipse Therapeutics, ...

 PRESS RELEASE

Revolutionize Preclinical Drug Candidate Discovery with Syntekabio

Syntekabio Inc. Revolutionize Preclinical Drug Candidate Discovery with Syntekabio 03-Jun-2023 / 15:40 CET/CEST The issuer is solely responsible for the content of this announcement.   Revolutionize Preclinical Drug Candidate Discovery with Syntekabio   NEWS RELEASE BY SYNTEKABIO, INC.   New York, NY | June 01, 2023 05:00 PM Eastern Daylight Time Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the launch of its cost-effective AI-based total solution service for finding new...

 PRESS RELEASE

Syntekabio at The BIO International Convention, June 5-8

Syntekabio Inc. Syntekabio at The BIO International Convention, June 5-8 03-Jun-2023 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement.   Syntekabio at The BIO International Convention, June 5-8 Discover one of the South Korean artificial intelligence drug development pioneers   NEWS RELEASE BY SYNTEKABIO, INC.   New York, NY | May 31, 2023 03:30 PM Eastern Daylight Time   Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery and development company, will exhibit at the BIO International Convention. The Conv...

 PRESS RELEASE

Syntekabio Inc.: 2023 Trends in New Drug Development

Syntekabio Inc. Syntekabio Inc.: 2023 Trends in New Drug Development 30-Jan-2023 / 18:20 CET/CEST 2023 Trends in New Drug DevelopmentThe webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital New York, N.Y. | January 30, 2023 10:00 AM Eastern Standard Time Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in a special webinar hosted by the New York Health Forum (NYHF) on the latest drug discovery and development trends. What is at the core of transforming a once len...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch